Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results, Misses Estimates By $0.02 EPS

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02), Briefing.com reports. The business had revenue of $0.04 million during the quarter. During the same period in the previous year, the firm earned ($1.27) EPS.

Keros Therapeutics Stock Up 2.2 %

Shares of NASDAQ:KROS opened at $45.38 on Friday. The company’s 50-day moving average price is $47.26 and its 200 day moving average price is $55.12. The company has a market cap of $1.64 billion, a PE ratio of -8.81 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KROS. Oppenheimer assumed coverage on Keros Therapeutics in a report on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company. Truist Financial restated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $92.17.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.